- Home
- SLNHP vs INM Comparison
SLNHP vs INM Comparison
Compare SLNHP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNHP | INM |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | Canada |
| Employees | 47 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLNHP | INM |
|---|---|---|
| Price | $9.50 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 150.0K |
| Earning Date | N/A | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,798,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.12 |
| 52 Week High | N/A | $8.27 |
Technical Indicators
Market Signals| Indicator | SLNHP | INM |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 36.25 |
| Support Level | $8.84 | $1.18 |
| Resistance Level | $9.94 | $1.35 |
| Average True Range (ATR) | 1.14 | 0.10 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 78.11 | 6.39 |
Price Performance
Historical ComparisonAbout SLNHP Soluna Holdings Inc 9.0% Series A Cumulative Perpetual Preferred Stock
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.